Indivior Completes Redomiciliation, Shifts Parent Company to U.S.

Event summary

  • Indivior Pharmaceuticals Inc. (INDV) has completed its redomiciliation from the UK to the United States.
  • A new Delaware corporation, Indivior Pharmaceuticals, Inc. (IPI), now serves as the parent company, with Indivior PLC renamed Indivior Ltd. and becoming a wholly-owned subsidiary.
  • Shareholders of Indivior PLC received one share of IPI for each share held, approved at an EGM on December 11, 2025.
  • The last day of trading for Indivior PLC ordinary shares on Nasdaq was January 23, 2026.
  • IPI is now subject to SEC reporting requirements and Nasdaq exchange rules.

The big picture

Indivior's redomiciliation reflects a broader trend of pharmaceutical companies seeking to optimize their capital markets access and governance structures within the U.S. While the move aims to strengthen its U.S. presence and potentially increase its valuation, the benefits are contingent on successful execution and favorable market conditions. The shift also highlights the ongoing scrutiny and regulatory landscape surrounding opioid treatment providers.

What we're watching

Index Inclusion
The company's inclusion in U.S. equity indices will be a key indicator of investor sentiment and liquidity, and whether the move delivers on the stated goal of increased indexation.
Governance Impact
The simplification of corporate governance, while touted as a benefit, will need to be demonstrably reflected in operational efficiency and decision-making speed to justify the restructuring.
SUBLOCADE® Collaboration
The stated intention to foster closer collaboration with public health leaders on SUBLOCADE® will be tested by the company's ability to secure and execute on new partnerships and initiatives.

Related topics

Pharmaceuticals